Best-in-RAS
Redefining what’s possible in precision oncology to treat RAS-dependent cancers
Redefining what’s possible in precision oncology to treat RAS-dependent cancers
We are a clinical-stage company unraveling the complex role of RAS in cancer to drive drug discovery & development
Our mission is to accelerate scientific and medical breakthroughs and deliver well-tolerated medicines with greater efficacy and safety to people with the deadliest cancers.
We uncover novel approaches targeting the RAS signaling pathway so that we can translate findings into clinical applications near term.
With a trusted team of world-leading RAS cancer biologists, expert medicinal chemists, and proven drug developers, our collaborative ecosystem creates novel RAS-targeted small molecules to maximize patient benefit.
Going beyond current approaches,
we aim to inhibit the active “ON” state.
Decades of scientific research demonstrating the crucial role of RAS signaling in cancer has culminated in the opportunity to translate our knowledge into real-world solutions for patients.
We use our expert understanding of RAS signaling biology to inform rational drug design, yielding multiple approaches, including the selective inhibition of RAS-driven PI3K activation and a broad spectrum of KRAS mutants in both the “ON” and “OFF” states.
We’re overcoming the limitations of current RAS-targeted approaches, aiming to realize the full promise of KRAS and PI3K inhibition.
A direct inhibitor targeting the “ON” and “OFF” states of KRAS. We are currently enrolling the ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer (NSCLC).
ONKORAS-101 is an open-label, multi-center Phase 1a/1b study designed to evaluate the safety, tolerability, preliminary antitumor activity, and pharmacokinetics of BBO-8520 as a single agent and in combination with pembrolizumab in patients with KRASG12C mutant NSCLC.
April 2024 • AACR 2024
January 2024 • Journal of Biological Chemistry
October 2023 • AACR-NCI-EORTC 2023
September 2023 • Targeting RAS Symposium 2023
September 2023 • Hanson Wade RAS-Targeted Drug Development Summit
Professor of Tumor Biology and Cancer Research at UC San Francisco and Advisor to the National Cancer Institute’s RAS Initiative at Frederick National Laboratory for Cancer Research
Chairman
Founder & Chief Executive Officer at BridgeBio Pharma
Director
Managing Director at Cormorant Asset Management
Director
Partner, Head of Corporate Development at Omega Funds
Director
September 9, 2024
Are you interested in joining our team, learning more or partnering with us? Get in touch by filling out the contact form below.
Explore open positions and stay-up-to date with BBOT on LinkedIn.